Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
- Status
- TERMINATED
- Phase
- PHASE1
Plasma-Adapted First-Line Pembro In NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
- Status
- COMPLETED
- Phase
- PHASE2
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)
- Status
- COMPLETED
- Phase
- PHASE2
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
- Status
- TERMINATED
- Phase
- PHASE2
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE2